Clinical Trials Sponsored by Innovate UK

Total 1610 results

Xiamen Innovax Biotech Co., Ltd

Completed

A Study on the Recombinant Hepatitis E Vaccine (Escherichia Coli) (Accelerated Vaccination Schedule)

Hepatitis E

China
Xiamen Innovax Biotech Co., Ltd

Completed

A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)

Hepatitis B | Hepatitis E

China
Center for Innovative Public Health Research

Recruiting

Sexual Health Advocacy for Guys - a Text Messaging-based HIV Prevention Program for Guys Who Are Into Guys (SHAG)

HIV Infections

United States
Stanford University
Stanford's Innovative Medicines Accelerator

Recruiting

Fluorescent Probe VGT-309 to ID Cancerous Colorectal Lesions During Augmented Colonoscopy

Colorectal Cancer

United States
Foundation for Innovative New Diagnostics, Switzerland

Not yet recruiting

Evaluating Next Generation LAM Assays and Molecular Diagnostics (POC and Near POC) for the Diagnosis of TB Among People With Presumptive TB: a Prospective Multicentre Diagnostic Accuracy Study (DriveDx4TB)

Tuberculosis
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Phase 2 Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

Advanced Solid Tumors Harboring NTRK Fusion | Primary Central Nervous System Tumors Harboring NTRK Fusion

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus, SLE

China
Beijing InnoCare Pharma Tech Co., Ltd.

Not yet recruiting

A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

Patients With Advanced Solid Tumors

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia

Primary Immune Thrombocytopenia

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

Treatment-naїve Mantle Cell Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors

Solid Tumors

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)

MZL

China
Innovative Cardiovascular Solutions
Meditrial Europe Ltd.

Completed

European Study Evaluating the EMBLOK Embolic Protection System During TAVR

Aortic Valve Disease

Italy
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
Foundation for Innovative New Diagnostics, Switzerland

Completed

Novel Rapid POC Diagnostics for COVID-19

COVID-19 Respiratory Infection

Georgia, South Africa
Foundation for Innovative New Diagnostics, Switzerland

Completed

Evaluation of the Performance of Rapid Diagnostics for SARS-CoV-2 Self-testing in the Hands of Untrained (CV009)

COVID-19

South Africa, Uganda
Novartis Pharmaceuticals
Innovative Medicines Initiative

Terminated

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis

Bronchiectasis

Germany, Spain, United Kingdom, China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)

Mantle Cell Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis

China, United States, Ukraine, Poland
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects

Healthy Subject

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

DDI Study of Orelabrutinib

Healthy Person

China
Foundation for Innovative New Diagnostics, Switzerland

Completed

Truenat™ HCV RNA Assay Evaluation

Hepatitis C

Denmark, Ethiopia, Georgia, Thailand, Ukraine
Foundation for Innovative New Diagnostics, Switzerland

Completed

Evaluation of the DPP II Assay in Laos

Acute Febrile Illness

Lao People's Democratic Republic
Foundation for Innovative New Diagnostics, Switzerland

Completed

DBS Evaluation of Fujirebio INNOTEST® HCV Ab IV

Hepatitis C Virus Infection

Ukraine
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

ADME Study of [14C]ICP-022 in Healthy Males

Healthy Volunteers

China
French Innovative Leukemia Organisation
Fresenius Kabi

Completed

Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients (FAMYLY)

Acute Myeloid Leukemia (AML)

France
Foundation for Innovative New Diagnostics, Switzerland

Completed

Evaluation of Point-of-care Tests for the Diagnosis of Cutaneous Leishmaniasis in Afghanistan (CLeishPOCAFG)

Cutaneous Leishmaniases
Foundation for Innovative New Diagnostics, Switzerland

Completed

Accuracy and Feasibility of Xpert Ultra

Tuberculosis, Pulmonary

Belarus, Georgia, India, South Africa
Gruppo Italiano Terapie Innovative nei Linfomi

Completed

Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.

Diffuse Large B-Cell Lymphoma

Italy
French Innovative Leukemia Organisation
Celgene Corporation

Completed

Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)

Acute Myeloid Leukemia

France
University Hospital, Lille
Innovative Medicines Initiative

Completed

Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development (PharmacogWP3)

Alzheimer Disease | Battery

France
Genovate Biotechnology Co., Ltd.,
Allergan Medical

Unknown

Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy

Glaucoma

Taiwan
NHS Greater Clyde and Glasgow
INNOVATEUK

Not yet recruiting

The PARS Study: Paediatric Advanced Respiratory Service Study - An Observational Diagnostic Feasibility Study (PARS)

Sleep Disordered Breathing | Apnea of Prematurity | Respiratory Rate

United Kingdom
Foundation for Innovative New Diagnostics, Switzerland

Recruiting

BGM and HbA1c POC Device Evaluation

Diabetes

Nigeria, Cambodia, Colombia
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia

Chronic Primary Immune Thrombocytopenia (ITP)

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject

Hepatic Impairment

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma (ICC)

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations

Advanced Solid Tumor

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-192 in Patients With Advanced Solid Tumors

Advanced Solid Tumors | Cholangiocarcinoma | Urothelial Carcinoma

Australia, United States
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Clinical Study of ICP-192 in Solid Tumors Patients

Solid Tumor

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study of ICP-022 in Patients With R/R DLBCL (DLBCL)

Diffuse Large B Cell Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

Waldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia Refractory

China
Foundation for Innovative New Diagnostics, Switzerland

Completed

COVID-19 Novel Molecular Point of Care Diagnostics Evaluation

COVID-19 Respiratory Infection

Switzerland, Uganda, United Kingdom
Foundation for Innovative New Diagnostics, Switzerland

Completed

Clinical Evaluation of tNGS for Diagnosis of DR-TB (Seq&Treat)

Tuberculosis, Multidrug-Resistant

Georgia, India, South Africa
French Innovative Leukemia Organisation
Janssen, LP

Active, not recruiting

Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (IDA53)

Relapsed or Refractory Chronic Lymphocytic Leukemia

France
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Hematoma

China

Clinical Trials Sponsored by Innovate UK

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations